Beyond Air, Inc. · NASDAQ:XAIR
Beyond Air — Q3 2026 Earnings Presentation
21 slides from Beyond Air's earnings presentation, Feb 13, 2026
Slide 1: Corporate Presentation
Corporate Presentation February 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the “Company”) nor shall there be any sale of securities in any
Slide 3: Beyond Air: The Nitric Oxide (NO) Company
Beyond Air: The Nitric Oxide (NO) Company Disruptive, Commercial-Stage Med Device Company - FDA- and CE-marked LungFit® PH in active hospital use - Addressing a ~$350M U.S. and $700M+ global market today 1, 2 - Anticipating $1B+ global NO Therapy market Our Technology Advantage Generates NO fr
Slide 4: Financial and Patent Information
Financial and Patent Information FY 2026 Revenue Guidance: $8m - $10m Financial Overview Dec 31, 2025 ProForma Ticker XAIR Cash2 $22.3 million Exchange NASDAQ Debt3 $22.0 million 2Represents cash, cash equivalents, restricted cash & marketable securities Share Price $1.15 (as of 2/6/26) 3Debt includ
Slide 5: The Evolution of iNO Technology
The Evolution of iNO Technology No Tanks. No Chemicals. Cylinder-Based Systems Cartridge/Chemical Systems Tankless System Tank-based delivery. Chemical cartridge-based NO generation. Simple, efficient, sustainable. Large footprint, heavy, logistics- dependent. **Not yet approved Mallinckrodt Praxair
Slide 6: LungFit PH Commercial Opportunity
LungFit PH Commercial Opportunity ® FDA approved and CE Marked (European Approval) for term and near-term neonates with hypoxic respiratory failure (aka persistent pulmonary hypertension of the newborn (PPHN)) CE Marked for the treatment of peri- and post-operative pulmonary hypertension in conj
Slide 7: LungFit PH I Ex-U.S. Current State
LungFit PH I Ex- U.S. Current State 21 40 21 Distributor Countries Countries Registered Contracts Signed Represented to Sell We have already received repeat orders in some countries.
Slide 8: LungFit PH Commercial Opportunity
LungFit PH Commercial Opportunity ® Executing With LungFit PH Generation 1 105% revenue growth for quarter ending December 2025 (v. December 2024) Executing With LungFit PH Generation 2 LungFit® PH II transport-ready system submitted to FDA as PMA supplement in June 2025 – Designed for ground an
Slide 9: LungFit PH: All You Need Is Air
LungFit PH: All You Need Is Air ® ® LungFit PH uses patented Plasma Pulse Technology to generate Let’s Go Head-to-Head Any competitor unlimited nitric oxide from ambient air Anytime within seconds, eliminating the need for Anywhere sourcing NO from cylinders or cassettes. Confidently deliver
Slide 10: Our Patented Plasma Pulse Technology
Our Patented Plasma Pulse Technology LungFit® PH is the first and only FDA and EU-approved system to generate continuous, unlimited NO from room air. Oxygen 60 Watts Nitric Oxide (NO) NO2 Smart Filter Nitrogen Electrode Nitrogen Dioxide (NO2) 10 Main and Backup Generators For illustrative purposes
Slide 11: How We Win
How We Win Cylinder Systems Genosyl DS Feature LungFit® PH (Mallinckrodt, Linde, Airgas) (Vero) Cassette of N2O4 converts to NO2 then NO at NO Supply Source Room Air (Unlimited) Compressed NO Gas (~40lb cylinder) bedside No Supply Duration Unlimited Variable (12-200 hours) Variable (1.6-35 hours) NO
Slide 12: LungFit PH: The Future of Clean iNO Is Here
LungFit® PH: The Future of Clean iNO is Here At Beyond Air, sustainability isn’t an add on, it’s engineered into everything we do. No Tanks: Eliminates cylinder storage, handling, and transport for a clean, simple iNO supply chain. Zero Hazardous Materials: No high-pressure gases or chemical car
Slide 13: Evolution of the LungFit PH
Evolution of the LungFit® PH An initial launch that shaped a faster, smarter development path for the next generation device. Learn Fix Advance Market Launch & Real-World Use Rapid Iteration Proven Platform, Clear Path Forward Gen 1 launch validated tankless, Several targeted engineering updates
Slide 14: The LungFit PH Generation II Device
The LungFit® PH Generation II Device LungFit® PH II Features Designed for air and ground transport Designed for MRI conditional use Filter visible and easier to change Improved user interface (touchscreen) Alarms Adjustable volume Flashing lights/screen Automated back-up Ionizer and
Slide 15: Nitric Oxide: A Magic Molecule?
Nitric Oxide A Magic Molecule?
Slide 16: Nitric Oxide Revolution
Nitric Oxide Revolution We are 100% focused on inhaled NO Driving the NO revolution with our LungFit® technology that generates NO on-demand from ambient air Approved Under FDA Review Investigational Hospital ICU* Hospital ICU+ Hospital Setting+ At-Home Treatment+ Smaller, lighter weight and designe
Slide 17: Nitric Oxide: A Simple, Yet Complex Molecule
Nitric Oxide: A Simple, Yet Complex Molecule Nitric oxide synthase (NOS) exists in 3 isoforms in the human body and has multiple functions. • Nitric Oxide (NO) is the combination of Type Location Mechanism Therapeutic Target nitrogen and oxygen in a specific manner • NO is a free radical gas that th
Slide 18: LungFit GO For Treating Lung Infections
LungFit GO For Treating Lung Infections* ® 5,000+ Treatments 170+ Patients 12 Different 0 Serious Adverse Administered Treated Clinical Settings Events Related to NO Chronic, Refractory Lung Infections are a Major Unmet Medical Need • Treatment at home with LungFit® can address this >$10b market • U
Slide 19: Non-LungFit NO Programs - NNOS
Non-LungFit® NO Programs - NNOS Drug Drug Therapeutic Area Proof of concept IND Enabling Ph 1 Ph 2 BA102 Autism spectrum disorder (ASD) Phelan McDermid Syndrome BA102 (PMS) BA102 Alzheimer’s Disease BA102 Early Onset Alzheimer’s BA101 Glioblastoma (GBM) For more information, visit neuro-nos.com Bi
Slide 20: Non-LungFit NO Programs – Cancer
Non-LungFit® NO Programs – Cancer Ultrahigh concentration NO >10,000 ppm to treat multiple types of solid tumors. For more information, visit beyondcancer.com Monotherapy Preclinical Ph 1 Ph 2 Next Milestone(*) Ph 3 NDA Commercial Cutaneous/ near cutaneous UNO Phase 1a completed tumors UNO Multiple
Slide 21: For More Information Contact
For more information contact: Investor Relations IR@beyondair.net www.beyondair.net